Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/07/2895310/8790/en/TG-Therapeutics-to-Participate-in-the-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/06/03/2892143/8790/en/TG-Therapeutics-to-Participate-in-the-Jefferies-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/31/2891466/8790/en/TG-Therapeutics-Announces-Presentations-for-BRIUMVI-ublituximab-in-Multiple-Sclerosis-at-the-2024-Consortium-of-Multiple-Sclerosis-Centers-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/28/2888922/8790/en/TG-Therapeutics-Announces-Schedule-of-Upcoming-Presentations-for-BRIUMVI-ublituximab-in-Multiple-Sclerosis-at-the-2024-Consortium-of-Multiple-Sclerosis-Centers-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/01/2873097/8790/en/TG-Therapeutics-Provides-Business-Update-and-Reports-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/04/30/2872825/8790/en/TG-Therapeutics-to-Host-Conference-Call-on-First-Quarter-2024-Financial-Results-and-Business-Update.html
https://www.globenewswire.com/news-release/2024/04/18/2865285/8790/en/TG-Therapeutics-Announces-Additional-Data-Presentations-for-BRIUMVI-ublituximab-xiiy-in-Multiple-Sclerosis-at-the-American-Academy-of-Neurology-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/04/18/2865236/8790/en/TG-Therapeutics-Awarded-National-Contract-by-the-Department-of-Veterans-Affairs-for-BRIUMVI-as-the-Preferred-Anti-CD20-for-Relapsing-Forms-of-Multiple-Sclerosis.html
https://www.globenewswire.com/news-release/2024/04/15/2862657/8790/en/TG-Therapeutics-Announces-Presentation-of-Data-for-BRIUMVI-ublituximab-xiiy-in-Multiple-Sclerosis-at-the-American-Academy-of-Neurology-2024-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/03/08/2843057/8790/en/TG-Therapeutics-Announces-Schedule-of-Data-Presentations-for-BRIUMVI-ublituximab-in-Multiple-Sclerosis-at-the-American-Academy-of-Neurology-2024-Annual-Meeting.html